Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
NEW YORK (
) is trading at unusually high volume Friday with 12 million shares changing hands. It is currently at two times its average daily volume and trading down 27 cents (-3.9%) at $6.58 as of 2:35 p.m. ET.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
MannKind has a market cap of $1.81 billion and is part of the health care sector and drugs industry. Shares are up 169.7% year to date as of the close of trading on Thursday.
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States.
TheStreet Ratings rates MannKind as a
. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins and weak operating cash flow. You can view the full
See all heavy volume stocks in our
or get investment ideas from our
Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE